VKTX Logo

Viking Therapeutics, Inc. (VKTX) 

NASDAQ
Market Cap
$7.33B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
759 of 776
Rank in Industry
421 of 433

Largest Insider Buys in Sector

VKTX Stock Price History Chart

VKTX Stock Performance

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in …

Insider Activity of Viking Therapeutics, Inc.

Over the last 12 months, insiders at Viking Therapeutics, Inc. have bought $0 and sold $87.28M worth of Viking Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Viking Therapeutics, Inc. have bought $224,995 and sold $37.06M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 90,000 shares for transaction amount of $222,390 was made by FOEHR MATTHEW W () on 2022‑05‑02.

List of Insider Buy and Sell Transactions, Viking Therapeutics, Inc.

2024-10-28SaleChief Financial Officer
131,687
0.1468%
$76.61$10.09M-4.26%
2024-10-25Saledirector
16,000
0.0185%
$79.50$1.27M0.00%
2024-10-25Saledirector
11,000
0.0129%
$80.89$889,7900.00%
2024-09-20SalePresident & CEO
216,130
0.1961%
$70.83$15.31M-7.82%
2024-09-20Saledirector
10,300
0.0092%
$69.50$715,850-7.82%
2024-08-21SalePresident & CEO
1,000
0.001%
$69.90$69,900-0.63%
2024-08-21Saledirector
5,700
0.0055%
$69.72$397,430-0.63%
2024-08-19SalePresident & CEO
112,870
0.1006%
$65.80$7.43M-3.27%
2024-08-19Saledirector
16,000
0.0135%
$62.22$995,453-3.27%
2024-08-14Saledirector
20,786
0.0186%
$57.53$1.2M0.00%
2024-07-30SalePresident & CEO
115,859
0.1065%
$57.58$6.67M-5.08%
2024-07-30SaleChief Operating Officer
18,026
0.0164%
$57.13$1.03M-4.35%
2024-07-30SaleChief Financial Officer
16,136
0.0147%
$57.15$922,212-4.38%
2024-05-03SaleChief Financial Officer
66,756
0.0587%
$74.69$4.99M-18.31%
2024-05-01SaleChief Operating Officer
281,425
0.2627%
$78.66$22.14M-17.58%
2024-02-09SalePresident & CEO
45,000
0.0564%
$29.90$1.35M+111.41%
2024-02-08SalePresident & CEO
269,079
0.3033%
$26.87$7.23M+123.71%
2024-02-08Saledirector
25,000
0.0294%
$28.05$701,250+123.71%
2024-01-31SalePresident & CEO
85,000
0.0881%
$24.71$2.1M+166.57%
2024-01-30SalePresident & CEO
35,000
0.0352%
$23.95$838,250+169.23%

Insider Historical Profitability

31.6%
SINGLETON J MATTHEWdirector
9500
0.0085%
$65.8115<0.0001%
FOEHR MATTHEW W
111250
0.0998%
$65.8151+1.66%
MACARTNEY LAWSONdirector
47965
0.043%
$65.8113+92.12%
Rowland Charles A Jrdirector
30000
0.0269%
$65.8111+92.12%
Webster Stephen Wdirector
8000
0.0072%
$65.8110+92.12%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$1.34B14.8316.35M+8.95%+$110.12M0.09
BlackRock$678.48M7.58.27M+8.79%+$54.8M0.02
The Vanguard Group$638.43M7.067.79M+44.66%+$197.11M0.01
Avoro Capital Advisors Llc$294.38M3.263.59MNew+$294.38M3.53
State Street$272.78M3.023.33M-41.98%-$197.33M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.